<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542655</url>
  </required_header>
  <id_info>
    <org_study_id>EFEX-OA_Protocol_Final_v1.1</org_study_id>
    <nct_id>NCT04542655</nct_id>
  </id_info>
  <brief_title>The Effect of Exercise on Serum Levels of Collagen and Proteoglycan in Patients With Knee Osteoarthritis (EFEX-OA-01)</brief_title>
  <acronym>EFEX-OA-01</acronym>
  <official_title>An Open-label, Single-center, Randomized, Controlled, Exploratory Study to Investigate the Effect of Weight Bearing Versus Non-weight Bearing Exercise on Collagen and Proteoglycan in Serum and Urine in Patients With Osteoarthritis and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NBCD A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Bioscience A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of EFEX-OA-01: To explore how running, cycling and resting acutely influence levels of&#xD;
      collagen and proteoglycan in patients with osteoarthritis knee and in young healthy subjects,&#xD;
      as reflected by changes in serum and urine biochemical markers originating from joint related&#xD;
      collagens and proteoglycans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Actual">May 14, 2019</completion_date>
  <primary_completion_date type="Actual">May 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to an order of exercise-intervention: cycling, running. This will be followed by a resting intervention. Interventions are planned 1 week apart.&#xD;
Blood will be sampled before, immediately after and again at 1, 2, 3 and 24 hours after intervention start. Spot urine is sampled before, after and the next day.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in biomarkers (exploratory)</measure>
    <time_frame>Acute: 0-4 hours and subacute: 24 hours</time_frame>
    <description>Serum and urine biochemical markers of collagen and proteoglycan turnover</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Cycling first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ergometer cycling then treadmill running then rest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Running first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treadmill running then ergometer cycling then rest</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ergometer Cycling followed by treadmill running</intervention_name>
    <description>The participants undergo ergometer cycling, treadmill running and rest.</description>
    <arm_group_label>Cycling first</arm_group_label>
    <other_name>Exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treadmill Running followed by ergometer cycling</intervention_name>
    <description>The participants undergo treadmill running, ergometer cycling and rest.</description>
    <arm_group_label>Running first</arm_group_label>
    <other_name>Exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rest</intervention_name>
    <description>The participants undergo ergometer cycling, treadmill running and rest.</description>
    <arm_group_label>Cycling first</arm_group_label>
    <arm_group_label>Running first</arm_group_label>
    <other_name>Non Exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for OA patients:&#xD;
&#xD;
          1. Kellgren-Lawrence radiological grade of 1-3 in at least one tibio-femoral joint&#xD;
             diagnosed by screening x-ray.&#xD;
&#xD;
          2. 35 to &lt; 75 years of age at the time of signing the informed consent form.&#xD;
&#xD;
          3. Bodyweight &gt; 50 and &lt; 150 kg and a BMI in the range 18,5-35 kg/m2.&#xD;
&#xD;
          4. Are male or female.&#xD;
&#xD;
          5. Is able to meet for all of the four study visits and comply with the dietary and&#xD;
             activity restrictions.&#xD;
&#xD;
          6. Can give informed consent.&#xD;
&#xD;
        Exclusion criteria for OA patients:&#xD;
&#xD;
        Medical conditions:&#xD;
&#xD;
          1. History of arthroscopy or intra-articular administration of corticosteroids or&#xD;
             hyaluronic acid into the target knee within 6 months before screening.&#xD;
&#xD;
          2. Kellgren-Lawrence radiological grade of 4 in at least one tibio-femoral joint&#xD;
&#xD;
          3. Previous arthroplasty of knee or hip.&#xD;
&#xD;
          4. Intention of having major surgery during the timeframe of this study.&#xD;
&#xD;
          5. OA related to eg. dysplasia, aseptic osteonecrosis, acromegaly, Paget disease,&#xD;
             Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout) or calcium&#xD;
             pyrophosphate deposition disease.&#xD;
&#xD;
          6. Current treatment with beta-receptor adrenergic antagonists (beta-blockers), systemic&#xD;
             corticosteroid treatment in doses equivalent to &gt; 10 mg of prednisolone per day, or&#xD;
             Vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated&#xD;
             heparin&#xD;
&#xD;
          7. Active systemic infection.&#xD;
&#xD;
          8. Active systemic inflammatory or autoimmune disease.&#xD;
&#xD;
          9. Symptomatic occlusive arterial disease e.g. claudication intermittens.&#xD;
&#xD;
         10. Heart failure &gt; NYHA class II.&#xD;
&#xD;
         11. History of transient ischaemic attack or stroke.&#xD;
&#xD;
         12. ECG findings which, in the opinion of the investigator, compromises patient safety&#xD;
             related to HRmax-test.&#xD;
&#xD;
         13. History of coronary artery disease, myocardial infarction, or other serious&#xD;
             cardiovascular disease, as evaluated by the investigator.&#xD;
&#xD;
         14. Is not currently active athlete or a highly trained individual.&#xD;
&#xD;
        Inclusion criteria for healthy subjects:&#xD;
&#xD;
          1. 18 to &lt; 75 years of age at the time of signing the informed consent form.&#xD;
&#xD;
          2. Have a bodyweight within &gt; 50 and &lt; 150 kg and a BMI within the range 18,5-35 kg/m2.&#xD;
&#xD;
          3. Are male or female.&#xD;
&#xD;
          4. Is able to meet for all of the four study visits and comply with the dietary and&#xD;
             activity restrictions.&#xD;
&#xD;
          5. Can give informed consent.&#xD;
&#xD;
        Exclusion criteria for healthy subjects:&#xD;
&#xD;
          1. History of arthroscopy or intra-articular administration of corticosteroids or&#xD;
             hyaluronic acid into the target knee within 6 months before screening.&#xD;
&#xD;
          2. Previous arthroplasty of knee or hip.&#xD;
&#xD;
          3. Intention of having major surgery during the timeframe of this study.&#xD;
&#xD;
          4. Secondary OA e.g. because of dysplasia, aseptic osteonecrosis, acromegaly, Paget&#xD;
             disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout) or&#xD;
             calcium pyrophosphate deposition disease.&#xD;
&#xD;
          5. Current treatment with beta-receptor adrenergic antagonists (beta-blockers), systemic&#xD;
             corticosteroid treatment in doses equivalent to &gt; 10 mg of prednisolone per day, or&#xD;
             Vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated&#xD;
             heparin&#xD;
&#xD;
          6. Any known active systemic infection.&#xD;
&#xD;
          7. Any known active systemic inflammatory or autoimmune disease.&#xD;
&#xD;
          8. Symptomatic occlusive arterial disease e.g. Inermittent claudication.&#xD;
&#xD;
          9. Heart failure &gt; NYHA class II.&#xD;
&#xD;
         10. History of transient ischaemic attack or stroke.&#xD;
&#xD;
         11. History of coronary artery disease, myocardial infarction, or other serious&#xD;
             cardiovascular disease, as evaluated by the investigator.&#xD;
&#xD;
         12. ECG findings which, in the opinion of the investigator, compromises patient safety&#xD;
             related to HRmax-test.&#xD;
&#xD;
         13. Is not currently active athlete or a highly trained individual.&#xD;
&#xD;
         14. X-ray verified Kellgren-Lawrence grade 1-4.&#xD;
&#xD;
         15. Is clinically suspected of having hip OA.&#xD;
&#xD;
        Other exclusions (all subjects):&#xD;
&#xD;
          1. Legal incapacity or limited legal capacity&#xD;
&#xD;
          2. Inability to communicate or cooperate with the investigator or to comply with the&#xD;
             requirements of the entire study.&#xD;
&#xD;
          3. Are categorized as being very difficult to draw blood from, as evaluated by the&#xD;
             investigator.&#xD;
&#xD;
          4. Current alcohol abuse and/or inability to refrain from intake of alcoholic beverages&#xD;
             24 hours prior to study intervention.&#xD;
&#xD;
          5. Other factors e.g. self-reported drug abuse, which in the opinion of the investigator&#xD;
             may interfere with the study conduct.&#xD;
&#xD;
          6. Site staff, study staff members and study staff family members.&#xD;
&#xD;
          7. Other concomitant disease compromising or otherwise significantly affecting ECM&#xD;
             turnover in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Nielsen, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanos Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

